AT 13148

Drug Profile

AT 13148

Alternative Names: AT-13148

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astex Therapeutics; Cancer Research UK; The Institute of Cancer Research
  • Developer Astex Pharmaceuticals; Cancer Research UK
  • Class Antineoplastics; Benzamides; Piperidines; Small molecules
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 May 2016 Phase-I development is ongoing in United Kingdom
  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 30 May 2012 Phase-I clinical trials in solid tumours in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top